Table 1

Summary table of prospective, multicentre clinical trials that have at least 1 year following Aquablation treatment

PopulationStudy typeDatesCountryAquablation procedures% 1 year visit completed
WATER (Gilling et al, 2019)16Moderate to severe LUTS due to BPH, 30–80 mL prostate sizeRandomised, controlled trial2015–17Australia, New Zealand, UK, USA11699.1%
WATER II (Bhojani et al, 2019)17Moderate to severe LUTS due to BPH, 80–150 mL prostate sizeSingle-arm with objective performance criteria, controlled trial2016–17Canada, USA10195.0%
FRANCAIS WATER (Misrai et al, 2019)11Moderate to severe LUTS due to BPH, 30–80 mL prostate sizeSingle-arm with objective performance criteria, controlled trial2017–18France30100%
OPEN WATER (Bach et al, 2020)10Moderate to severe LUTS due to BPH, 20–150 mL prostate sizeObservational study2017–19Australia, Germany, Lebanon, New Zealand, UK17880.9%
  • BPH, benign prostatic hyperplasia; LUTS, lower urinary tract symptoms.